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Abstract
Abnormal activation of Mer kinase has been implicated in the oncogenesis of many human
cancers including acute lymphoblastic and myeloid leukemia, non-small cell lung cancer, and
glioblastoma. We have discovered a new family of small molecule Mer inhibitors,
pyrazolopyrimidine sulfonamides, that potently inhibit the kinase activity of Mer. Importantly,
these compounds do not demonstrate significant hERG activity in the PatchXpress assay. Through
structure-activity relationship studies, 35 (UNC1062) was identified as a potent (IC50 = 1.1 nM)
and selective Mer inhibitor. When applied to live tumor cells, UNC1062 inhibited Mer
phosphorylation and colony formation in soft agar. Given the potential of Mer as a therapeutic
target, UNC1062 is a promising candidate for further drug development.
Keywords
Mer inhibitors; pyrazolopyrimidines; sulfonamides; leukemia; non-small cell lung cancer;
glioblastoma
© 2013 Elsevier Masson SAS. All rights reserved.
*Corresponding Author: Tel: 919-843-8456. Fax: 919-843-8465. xiaodonw@unc.edu.
¶These authors contributed equally
$Present Address: 195 Blackhorse Ln, North Brunswick, NJ 08902.
SUPPORTING INFORMATION Experimental details and characterization of all compounds and biological methods. This material is
available free of charge via the internet at http://pubs.acs.org.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
NIH Public Access
Author Manuscript
Eur J Med Chem. Author manuscript; available in PMC 2014 July 01.
Published in final edited form as:














Mer belongs to the TAM (Tyro3, Axl, and Mer) family of receptor tyrosine kinases
(RTKs).1 Under normal physiological conditions, Mer kinase promotes cell proliferation and
survival, platelet aggregation, macrophage clearance of apoptotic cells, and cytokine
release.2 Abnormal activation of Mer has been implicated in the oncogenesis of many
human cancers and is often associated with poor prognostic indicators.2–3 For example, Mer
is ectopically expressed in both B- and T-cell acute lymphoblastic leukemias (ALL)4 but not
in normal mouse and human T- and B-lymphocytes at any stage of development. Similarly,
Mer is expressed in the majority of acute myeloid leukemia (AML) cell lines and patient
samples but not in normal bone marrow myeloid cells.5 Finally, Mer is frequently
overexpressed in solid tumors, including non-small cell lung cancer (NSCLC) cell lines6 and
patient samples, even though normal human bronchial epithelial (NHBE) cells and lung
tissue adjacent to tumors do not express Mer protein.6 Similar findings have been reported
in other solid tumors, including glioblastoma (GBM)3b, 7 and metastatic melanoma.8 This
tumor specific expression pattern may confer a large therapeutic window - at least in these
tumor types. Expression of a Mer transgene in hematopoietic cells leads to development of
leukemia and/or lymphoma in mice.9 In addition, when Mer is inhibited by sh-RNA
knockdown in leukemia,4c NSCLC,6 or GBM cells,7a they are more susceptible to apoptotic
death and exhibit reduced colony formation in soft agar. Moreover, in orthotropic ALL and
AML xenograft mouse models, onset and progression of disease were delayed and survival
was significantly increased in mice transplanted with Mer knockdown leukemia cell lines
relative to mice transplanted with wild-type cell lines.4c, 5 Similarly, in a NSCLC xenograft
mouse model growth of tumors is markedly slowed by Mer knockdown. In addition, the
combination of standard cytotoxic chemotherapies with shRNA-mediated Mer knockdown
results in synergistic tumor cell killing. Taken together, these data demonstrate important
roles of Mer for oncogenesis and anti-apoptotic activity in multiple tumor types. Therefore,
Mer provides a novel therapeutic target for the treatment of ALL, AML, NSCLC, and other
Mer-related diseases. Consequently, Mer inhibitors are expected to both mediate direct anti-
tumor, proapoptotic effects and augment chemosensitivity in combination with standard
therapies.
Few small molecule Mer inhibitors have been reported,10 among them compound 1
(UNC569) (Figure 1) is the most promising one demonstrating inhibition of Mer at sub-
nanomolar concentrations.11 However, UNC569 has undesirable activity toward the human
ether-a-go-go-related gene potassium channel (hERG) in the conventional PatchXpress
assay (EC50 = 1.7 μM). 12 Inhibition of hERG could lead to long QT syndrome and sudden
death and is the reason for the withdrawal of several FDA-approved drugs.13 In an effort to
decrease the hERG activity of UNC569 through analog synthesis, we discovered that
sulfonamide 2 (Figure 1) had similar activity against Mer kinase with better physical
properties. Consequently, compound 2 is a better starting point than UNC569 to develop
potent Mer inhibitors as potential therapeutics. Herein we report the structure–activity
relationship (SAR) of a series of compounds related to 2 on inhibiting the TAM family
kinases and the discovery of potent Mer inhibitors with minimal hERG activity and
excellent cellular activity.
SYNTHESIS
The synthetic routes to sulfonamide analogues (Scheme 1) are similar to what we have
previously developed for the synthesis of analogues of UNC569.11 Briefly, 3-
chlorobenzoperoxoic acid (mCPBA) oxidation of the known compound 314 followed by the
displacement of the methyl sulfinyl/sulfonyl group by amines provided the intermediate 4,
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which was subsequently alkylated at the N1 position of the pyrazole ring to yield 5. Suzuki
coupling between 5 and a boronic acid provided the final product 6.
RESULTS AND DISCUSSION
Most hERG inhibitors contain a basic amine group and we thus speculate that the hERG
activity of 1 may be due to the presence of a primary amine (NH2) at the R2 position (Table
1). Consequently, we first synthesized a focused library of compounds with different R2
groups while keeping R1 fixed as N-methyl benzenesulfonamide. Inhibition of Mer kinase
activity by analogues was tested at the Km for ATP using a microfluidic capillary
electrophoresis (MCE) assay15 in which phosphorylated and unphosphorylated substrate
peptides were separated and analyzed using a LabChip EZ Reader. For comparison,
inhibition of other members in the TAM RTK family, Tyro3 and Axl, was also measured.
As shown in Table 1, when the NH2 group at the R2 position (2) was replaced by a hydroxyl
(OH) group (7), the activity of the analogue 7 was decreased 6-fold. Increasing the length of
the linker between the pyrazole ring and the cyclohexyl group also decreased the activity of
compounds (8, 9 vs 2). In contrast, when the length of the linker was shortened and R2 was
replaced with a trans-4-hydroxycyclohexyl group, the corresponding analogue 10 had
enhanced activity compared to the parent 7. More specifically, the IC50 value was changed
from 18 nM for 7 to 2.4 nM for 10, suggesting that the conformational rigidity and the size
of R2 was important for Mer inhibition. Consistent with this notion, analogs 12 and 13,
which featured open chain versions of cyclohexanol at the R2 position, had decreased Mer
inhibition. Using a tetrahydropyran to replace the 4-hydroxycyclohexyl group provided
analogues that were less active (14, 15 & 16). Furthermore, a cyclohexyl group alone at the
R2 position resulted in a 28-fold weaker inhibitor 17, which further confirmed our previous
observation: a hydrogen bond between the polar substituent at the R2 position with the
carbonyl of Arg727 of Mer protein was important.11 The configuration of the hydroxyl
group was not critical, as the cis-analogue 11 had similar activity as trans-10.
We also tested the activity of the synthetic analogues against Axl and Tyro3 to monitor their
selectivity for TAM family members and develop a pan-TAM SAR. In general, these
analogues showed modest selectivity within the TAM family and are generally less potent
against Axl and Tyro3. In addition, to test our hypothesis regarding on the cause of the
hERG activity, compounds 2 & 10 were characterized in the hERG binding assay. Indeed,
10 had no hERG activity in the PatchXpress assay while 2 was active with an EC50 of 3.2
μM. Removal of the primary amine at R2 position eliminated the binding of our compounds
to the hERG channel.
Next, the SAR at the R1 site was explored (Table 2). In general, these analogues are very
potent against Mer (at sub-nanomolar concentrations) and have good selectivity for Mer
over Axl (> 16 fold) and Tyro3 (> 9 fold). A reversed sulfonamide functional group (18),
sulfonic acid (19) and unsubstituted sulfonamide (20) at the R1 site were tolerated. When
one of the acidic hydrogens in sulfonamide was substituted with a small alkyl group such as
propyl (21) or iso-propyl (22), the activity of the analogues remained the same. In contrast, a
cycloalkyl group such as cyclopropyl (23), cyclopentyl (24) and cyclohexyl (25) at this
position yielded a more active analogue. A tetrahydropyran (26) or 4-piperidinylmethyl (28)
group was also well tolerated at this position while a para-fluorophenyl ring (27) was less
suitable. Interestingly, 29, the precursor of 28 with a Boc protection group at piperidinyl
nitrogen, was equally potent, which could be explained by the fact that the R1 position was
exposed to solvents as observed in the X-ray structure of UNC569 complexed with Mer.11
To further confirm this explanation, we introduced a large side chain at this position and
found that the corresponding derivative 30 was still active. Finally, when the acidic
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hydrogen on the sulfonamide functional group was replaced by a variety of alkyl groups, the
activity and TAM RTK-selectivity of the resulting analogues 31–36 were maintained.16
Compared to UNC569, 35 (UNC1062) had improved selectivity and activity against Mer
relative to other TAM family RTKs (78-fold selectivity over Axl and 36-fold over Tyro3).
Morrison tight-binding inhibition studies revealed that UNC1062 had a Ki of 0.33 nM
against Mer.17 These outstanding inhibitory profiles of UNC1062 prompted us to further
investigate its activity in intact cell systems.
The ability of UNC1062 to inhibit Mer auto-phosphorylation in different cell lines was first
tested. Briefly, human pre-B leukemia 697 cells were grown in suspension and treated with
various concentrations of UNC1062 for 1 h prior to addition of a phosphatase inhibitor to
stabilize phospho-Mer. Mer protein was immunoprecipitated from lysates and phospho-Mer
and total Mer proteins were detected by western blot. In this cell-based assay, the IC50 value
for inhibition of phospho-Mer by UNC1062 was 6.4 nM (Figure 2). In comparison, the IC50
of UNC569 in the same assay was 141 nM,11 suggesting that UNC1062 was significantly
more potent than UNC569 both with purified Mer kinase and in intact cells.
To determine if UNC1062 inhibits Mer phosphorylation in adherent cells, similar studies
were performed using a human, adherent, pediatric rhabdoid brain tumor cell line (BT-12)
and two NSCLC cell lines (A549 and Colo699). Inhibition of Mer phosphorylation was
evident in cells when the concentration of UNC1062 was above 300 nM (Figure 3A).
Similarly, phosphorylation of Mer was stably inhibited over 72 h of culture in A549 and
Colo699 NSCLC cells treated with 250 nM or 500 nM UNC1062 (Figure 3B). Thus, while
solid tumor cells require significantly higher concentrations of UNC1062 compared to non-
adherent leukemia cells, possibly as a result of decreased exposure across adherent cell
membranes, treatment with UNC1062 at sub-micromolar concentrations was sufficient to
inhibit Mer phosphorylation in adherent cell lines.
To determine if UNC1062 can mediate functional anti-tumor effects, BT-12, A549, and
Colo699 cells were cultured in soft agar overlaid with medium containing UNC1062 or
vehicle only. Treatment with 1.0 μM UNC1062 was sufficient to completely abrogate
growth of BT-12 rhabdoid tumor colonies in soft agar (Figure 4A). Similarly, treatment with
UNC1062 inhibited colony formation in both A549 and Colo699 NSCLC cultures.
Moreover, inhibition of colony formation in long-term soft agar assays and inhibition of Mer
phosphorylation in short-term assays occurred at similar concentrations of UNC1062 in
these cell lines, consistent with a causal relationship.
CONCLUSIONS
In summary, we have identified and synthesized a new family of small molecule Mer
inhibitors, pyrazolopyrimidine sulfonamides, which potently inhibit the kinase activity of
Mer. Importantly, this new generation of inhibitors do not show significant hERG activity in
the PatchXpress assay. Through structure-activity relationship studies, 35 (UNC1062) was
identified as both a potent (Ki = 0.33 nM) and selective Mer inhibitor. When applied to live
cells, UNC1062 inhibited Mer phosphorylation and colony formation in soft agar. These
results provide the first evidence of anti-tumor activity mediated by a member of this novel
class of inhibitors, thus further validate Mer as a drug target for cancer.
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Microwave reaction was carried out using a Discover-S reactor with a vertically-focused IR
external temperature sensor and an Explorer 72 autosampler. The dynamic mode was used
to set up the desired temperature and hold time with the following fixed parameters:
PreStirring, 1 min; Pressure, 200 psi; Power, 200 W; PowerMax, off; Stirring, high. Flash
chromatography was carried out on pre-packed silica gel disposable columns. Analytical
thin-layer chromatography (TLC) was performed with silica gel 60 F254, 0.25 mm pre-
coated TLC plates. TLC plates were visualized using UV254 or phosphomolybdic acid with
charring. All 1H NMR spectra were obtained with a 400 MHz spectrometer and 13C NMR
spectra were obtained with a 100 MHz spectrometer. Preparative HPLC was performed with
the UV detection at 220 or 254 nm. LC-MS was performed with the UV detection at 220
nm, 254 nm, and 280 nm, and a single quadrupole mass spectrometer using electrospray
ionization (ESI) source. High-resolution (positive ion) mass spectra (HRMS) were acquired
using a LCMS-TOF mass spectrometer.
Synthesis
3-Bromo-N-butyl-1H-pyrazolo[3,4-d]pyrimidin-6-amine (4)—To a mixture of 3-
bromo-6-(methylthio)-1H-pyrazolo[3,4-d] pyrimidine (24.5 g, 100 mmol) in THF (100 mL)
was added meta-chloroperoxybenzoic acid (33.7 g, 77%, 150 mmol) in portions at room
temperature. The white mixture was stirred for 2 h and transferred into a THF (50 mL)
solution of n-butylamine (49.4 mL, 500 mmol) at 0 °C. The resulting solution was heated at
60 °C for 2.0 h. After removal of the solvent under reduced pressure, MeOH was added and
the mixture was filtered. The white solid was washed with MeOH (3x) and dried to afford
the title compound 4 (23.6 g, 87%). 1H NMR (400 MHz, DMSO-d6) δ 8.59 (s, 1H), 7.63 (s,
1H), 3.37–3.11 (m, 3H), 1.54–1.41 (m, 2H), 1.29 (dq, J = 14.4, 7.3 Hz, 2H), 0.84 (t, J = 7.3
Hz, 3H); 13C NMR (100 MHz, DMSO-d6) δ 162.0, 157.4, 153.1, 120.5, 107.1, 41.0, 31.0,
20.1, 14.2; MS m/z 270.1 [M+H]+.
4-(1-((trans-4-Aminocyclohexyl)methyl)-6-(butylamino)-1H-pyrazolo[3,4-
d]pyrimidin-3-yl)-N-methylbenzenesulfonamide (2)—A mixture of 4 (0.054 g, 0.20
mmol), K2CO3 (0.11 g, 0.8 mmol), DMF (2.0 mL), and tert-butyl (trans-4-
(chloromethyl)cyclohexyl)carbamate (0.062 g, 0.25 mmol) in a 10 mL microwave tube was
heated under microwave irradiation at 150 °C for 10 min. After cooling to room
temperature, (4-(N-methylsulfamoyl)phenyl)boronic acid (0.065 g, 0.30 mmol), Pd(PPh3)4
(0.023 g, 0.020 mmol), and H2O (1.0 mL) were added sequentially. The resulting mixture
was stirred at room temperature for 1.0 min and then heated under microwave irradiation at
150 °C for 15 min. After cooling to room temperature, the mixture was quenched with H2O
and extracted with EtOAc (3x). The combined organic layer was dried (Na2SO4) and
concentrated. The residue was purified by an ISCO silica gel column to provide tert-butyl
(trans-4-((3-(4-(N-methylsulfamoyl)phenyl)-6-(butyllamino)-1H-pyrazolo[3,4-
d]pyrimidin-1-yl)methyl) cyclohexyl)carbamate as a white solid. This white solid was
dissolved in CH2Cl2 (2.0 mL), then was added TFA (0.5 mL) at room temperature. The
resulting solution was stirred for 1.0 h and was concentrated. The residue was purified by
prep-HPLC to provide the title compound 2 as a white solid (0.053 g, 48% over 3 steps). 1H
NMR (400 MHz, CDCl3) δ 1H NMR (400 MHz, CD3OD) δ 9.17 (s, 1H), 8.20–8.14 (m,
2H), 8.01–7.95 (m, 2H), 4.26 (d, J = 6.8 Hz, 2H), 3.52 (t, J = 7.1 Hz, 2H), 3.13–3.00 (m,
1H), 2.81 (s, 3H), 2.15 –2.01 (m, 3H), 1.86 (d, J = 12.0 Hz, 2H), 1.68 (dt, J = 12.7, 7.4 Hz,
2H), 1.48 (dt, J = 14.8, 7.3 Hz, 2H), 1.41–1.21 (m, 4H), 1.00 (t, J = 7.4 Hz, 3H); LC-MS:
>97% purity, tR = 4.379 min; MS m/z 472.3 [M+1]+.
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d]pyrimidin-3-yl)-N-methylbenzenesulfonamide (7)—(General Procedure A) A
mixture of 4 (0.054 g, 0.20 mmol), K2CO3 (0.11 g, 0.8 mmol), DMF (2.0 mL), and tert-
butyl((trans-4-(chloromethyl)cyclohexyl)oxy)dimethylsilane (0.066 g, 0.25 mmol) in a 10
mL microwave tube was heated under microwave irradiation at 150 °C for 10 min. After the
reaction was cooled to room temperature, (4-(N-methylsulfamoyl)phenyl)boronic acid
(0.065 g, 0.30 mmol), Pd(PPh3)4 (0.023 g, 0.020 mmol), and H2O (1.0 mL) were added
sequentially. The mixture was stirred at room temperature for 1.0 min and then heated under
microwave irradiation at 150 °C for 15 min. After cooling to room temperature, the mixture
was quenched with H2O and extracted with EtOAc (3x). The combined organic layers were
dried (Na2SO4) and concentrated. The residue was purified by an ISCO silica gel column to
provide 4-(1-((trans-4-((tert-butyldimethylsilyl)oxy)cyclohexyl)methyl)-6-(butylamino)-1H-
pyrazolo[3,4-d]pyrimidin-3-yl)-N-methylbenzenesulfonamide as a white solid. This white
solid was dissolved in THF (2.0 mL) and was added TBAF (1.0 M in THF, 1 mL) at room
temperature. The resulting solution was refluxed for 2.0 h and was concentrated. The residue
was purified by prep-HPLC to provide the title compound 7 (0.040 g, 44% over 3 steps) as a
white solid. 1H NMR (400 MHz, CDCl3) δ 9.30 (s, 1H), 8.20 (d, J = 8.0 Hz, 2H), 8.01 (d, J
= 8.0 Hz, 2H), 4.26 (d, J = 7.0 Hz, 2H), 3.58 (t, J = 7.2 Hz, 2H), 3.55–3.45 (m, 1H), 2.58 (s,
3H), 2.11–1.93 (m, 3H), 1.73 (td, J = 14.9, 7.9 Hz, 4H), 1.49 (dq, J = 14.8, 7.5 Hz, 2H),
1.32–1.14 (m, 4H), 1.02 (t, J = 7.7Hz, 3H); LC-MS: >97% purity, tR = 6.629 min; MS m/z
473.3 [M+1]+.
4-(1-(2-(trans-4-Hydroxycyclohexyl)ethyl)-6-(propylamino)-1H-pyrazolo[3,4-
d]pyrimidin-3-yl)-N-methylbenzenesulfonamide (8)—The title compound 8 (0.040
g, 42%) was prepared according to general procedure A from tert-butyl((trans-4-(2-
chloroethyl)cyclohexyl)oxy)dimethylsilane (0.069 g, 0.25 mmol) as a white solid. 1H NMR
(400 MHz, CDCl3) δ 8.79 (s, 1H), 7.92 (d, J = 8.6 Hz, 2H), 7.83 (d, J = 8.6 Hz, 2H), 4.24 (t,
J = 7.0 Hz, 2H), 3.45–3.30 (m, 3H), 2.50 (s, 3H), 1.81 (t, J = 11.5 Hz, 3H), 1.71 (dd, J =
13.7, 6.8 Hz, 2H), 1.53 (dt, J = 14.9, 7.3 Hz, 2H), 1.40–1.27 (m, 2H), 1.08 (dd, J = 23.1,
12.5 Hz, 4H), 1.00–0.89 (m, 2H), 0.86 (t, J = 7.9 Hz, 3H); LC-MS: >97% purity, tR = 5.759
min; MS m/z 487.3 [M+1]+.
4-(1-(3-(trans-4-Hydroxycyclohexyl)propyl)-6-(propylamino)-1H-pyrazolo[3,4-
d]pyrimidin-3-yl)-N-methylbenzenesulfonamide (9)—The title compound 9 (0.055
g, 56%) was prepared according to general procedure B from tert-butyl((trans-4-(3-
chloropropyl)cyclohexyl)oxy)dimethylsilane (0.069 g, 0.25 mmol) as a white solid. 1H
NMR (400 MHz, CDCl3) δ 9.03 (s, 1H), 8.17–8.09 (m, 2H), 7.99–7.92 (m, 2H), 4.32 (t, J =
6.9 Hz, 2H), 3.48 (t, J = 7.0 Hz, 2H), 3.42 (dt, J = 10.8, 4.2 Hz, 1H), 2.58 (s, 3H), 2.02–1.84
(m, 4H), 1.76 (d, J = 11.6 Hz, 2H), 1.66 (dt, J = 14.8, 7.3 Hz, 2H), 1.52–1.39 (m, 2H), 1.29–
1.13 (m, 5H), 0.99 (t, J = 7.4 Hz, 3H), 0.96–0.86 (m, 2H); LC-MS: >97% purity, tR = 5.856
min; MS m/z 501.3 [M+1]+.
4-(1-(trans-4-Hydroxycyclohexyl)-6-(propylamino)-1H-pyrazolo[3,4-
d]pyrimidin-3-yl)-N-methylbenzenesulfonamide (10) and 4-(1-(cis-4-
Hydroxycyclohexyl)-6-(propylamino)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-N-
methylbenzenesulfonamide (11)—(General Procedure B) A mixture of 4 (0.054 g,
0.20 mmol), K2CO3 (0.11 g, 0.8 mmol), DMF (2.0 mL), and 4-chlorocyclohexanol (0.081 g,
0.6 mmol) in a 10 mL microwave tube was heated under microwave irradiation at 200 °C for
30 min. After cooling to room temperature, (4-(N-methylsulfamoyl)phenyl)boronic acid
(0.065 g, 0.30 mmol), Pd(PPh3)4 (0.023 g, 0.020 mmol), and H2O (1.0 mL) were added
sequentially. The resulting mixture was stirred at room temperature for 1.0 min and then
heated under microwave irradiation at 150 °C for 15 min. After cooling to room
Liu et al. Page 6













temperature, the mixture was quenched with H2O and extracted with EtOAc (3x). The
combined organic layer was dried (Na2SO4) and concentrated. The residue was purified by
prep-HPLC to provide the title compounds 10 (0.011 g, 13% over 3 steps) and 11 (0.020 g,
23% over 3 steps) as white solids. 10: 1H NMR (400 MHz, CDCl3) δ 8.78 (s, 1H), 7.92 (d, J
= 8.4 Hz, 2H), 7.82 (d, J = 8.3 Hz, 2H), 4.51 (s, 1H), 3.64 (s, 1H), 3.37 (t, J = 7.0 Hz, 2H),
2.50 (s, 3H), 2.17–1.86 (m, 6H), 1.61–1.29 (m, 6H), 0.87 (t, J = 7.3 Hz, 3H); LC-MS: >97%
purity, tR = 5.402 min; HRMS (TOF, ESI+) m/z: [M+H]+ calculated for C22H31N6O3S,
459.2178; found 459.2155. 11: 1H NMR (400 MHz, CDCl3 + CD3OD) δ 8.82 (s, 1H), 7.95
(dd, J = 8.2, 6.2 Hz, 2H), 7.84 (dd, J = 8.5, 1.8 Hz, 2H), 4.66–4.48 (m, 1H), 3.44–3.33 (m,
3H), 2.53 (s, 3H), 2.46–2.32 (m, 1H), 1.99–1.81 (m, 3H), 1.79– 1.61 (m, 3H), 1.55 (dt, J =
14.8, 7.4 Hz, 2H), 1.36 (td, J = 14.8, 7.4 Hz, 3H), 0.88 (t, J = 7.3 Hz, 3H); LC-MS: >97%
purity, tR = 5.590 min; MS m/z 459.2 [M+1]+.
4-(1-(2-Hydroxyethyl)-6-(propylamino)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-N-
methylbenzenesulfonamide (12)—(General Procedure C) A mixture of 4 (0.054 g,
0.20 mmol), K2CO3 (0.11 g, 0.8 mmol), DMF (2.0 mL), and 2-bromoethanol (0.038 g, 0.30
mmol) in a 10 mL microwave tube was heated under microwave irradiation at 150 °C for 10
min. After cooling to room temperature, (4-(N-methylsulfamoyl)phenyl)boronic acid (0.065
g, 0.30 mmol), Pd(PPh3)4 (0.023 g, 0.020 mmol), and H2O (1.0 mL) were added
sequentially. The resulting mixture was stirred at room temperature for 1.0 min and then
heated under microwave irradiation at 150 °C for 15 min. After cooling to room
temperature, the mixture was quenched with H2O and extracted with EtOAc (3x). The
combined organic layers were dried (Na2SO4) and concentrated. The residue was purified
by an ISCO silica gel column to provide the title compound 12 (0.044 g, 57%) as a white
solid. 1 H NMR (400 MHz, CDCl3) δ 8.86 (s, 1H), 8.00–7.92 (m, 2H), 7.91–7.83 (m, 2H),
4.42 (t, J = 5.0 Hz, 2H), 4.01 (t, J = 5.0 Hz, 2H), 3.38 (t, J = 7.1 Hz, 3H), 2.56 (s, 3H), 1.63–
1.50 (m, 2H), 1.44–1.30 (m, 2H), 0.90 (t, J = 7.3 Hz, 3H); LC-MS: >97% purity, tR = 5.244
min; MS m/z 405.2 [M+1]+.
4-(1-(3-Hydroxypropyl)-6-(propylamino)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-N-
methylbenzenesulfonamide (13)—The title compound 13 (0.045 g, 56%) was prepared
according to general procedure C from 3-chloropropan-1-ol (0.029 g, 0.30 mmol) as a white
solid. 1H NMR (400 MHz, CDCl3) δ 8.88 (s, 1H), 7.98 (d, J = 8.6 Hz, 2H), 7.90 (d, J = 8.6
Hz, 2H), 4.43 (t, J = 6.2 Hz, 2H), 3.50 (t, J = 5.8 Hz, 2H), 3.40 (t, J = 7.1 Hz, 2H), 2.59 (s,
3H), 2.10–2.00 (m, 2H), 1.60 (dt, J = 14.9, 7.4 Hz, 2H), 1.40 (dq, J = 14.5, 7.3 Hz, 2H), 0.92
(t, J = 7.3 Hz, 3H); LC-MS: >97% purity, tR = 5.336 min; MS m/z 419.2 [M+1]+.
N-Methyl-4-(6-(propylamino)-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-
d]pyrimidin-3-yl)benzenesulfonamide (14)—(General Procedure D) A mixture of 4
(0.054 g, 0.20 mmol), K2CO3 (0.11 g, 0.8 mmol), DMF (2.0 mL), and 4-
chlorotetrahydro-2H-pyran (0.072 g, 0.60 mmol) in a 10 mL microwave tube was heated
under microwave irradiation at 200 °C for 30 min. After cooling to room temperature, (4-
(N-methylsulfamoyl)phenyl)boronic acid (0.065 g, 0.30 mmol), Pd(PPh3)4 (0.023 g, 0.020
mmol), and H2O (1.0 mL) were added sequentially. The resulting mixture was stirred at
room temperature for 1.0 min and then heated under microwave irradiation at 150 °C for 15
min. After cooling to room temperature, the mixture was quenched with H2O and extracted
with EtOAc (3x). The combined organic layers were dried (Na2SO4) and concentrated. The
combined organic layer was dried (Na2SO4) and concentrated under reduced pressure. The
residue was purified by an ISCO silica gel column to provide the title compound 14 as a
white solid (0.052 g, 61% over 2 steps). 1H NMR (400 MHz, CDCl3) δ 8.96 (s, 1H), 8.07
(d, J = 8.5 Hz, 2H), 7.97 (d, J = 8.5 Hz, 2H), 5.33 (s, 1H), 4.92–4.79 (m, 1H), 4.32 (dd, J =
10.8, 5.4 Hz, 1H), 4.17 (dd, J = 11.7, 3.3 Hz, 2H), 3.64 (dd, J = 11.9, 10.2 Hz, 2H), 3.52 (dd,
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J = 12.9, 6.9 Hz, 2H), 2.71 (d, J = 5.4 Hz, 3H), 2.48 (ddd, J = 25.0, 12.5, 4.7 Hz, 2H), 1.97
(d, J = 10.8 Hz, 2H), 1.66 (dt, J = 14.8, 7.2 Hz, 2H), 1.47 (dq, J = 14.5, 7.3 Hz, 2H), 0.99 (t,
J = 7.3 Hz, 3H); LC-MS: 96% purity, tR = 5.689 min; MS m/z 445.2 [M+1]+.
N-Methyl-4-(6-(propylamino)-1-((tetrahydro-2H-pyran-4-yl)methyl)-1H-
pyrazolo[3,4-d]pyrimidin-3-yl)benzenesulfonamide (15)—The title compound 15
(0.062 g, 70% over 2 steps) was prepared according to general procedure C from 4-
(bromomethyl)tetrahydro-2H-pyran (0.045 g, 0.25 mmol) as a white solid. 1H NMR (400
MHz, CDCl3) δ 8.95 (s, 1H), 8.10–8.03 (m, 2H), 8.00–7.93 (m, 2H), 5.37 (bs, 1H), 4.41–
4.30 (m, 1H), 4.24 (d, J = 7.1 Hz, 2H), 4.03–3.91 (m, 2H), 3.51 (dd, J = 13.0, 6.9 Hz, 2H),
3.38 (td, J = 11.5, 2.6 Hz, 2H), 2.71 (d, J = 5.4 Hz, 3H), 2.40 – 2.24 (m, 1H), 1.71–1.61 (m,
2H), 1.60–1.56 (m, 1H), 1.54–1.38 (m, 5H), 0.99 (t, J = 7.3 Hz, 3H); LC-MS: >97% purity,
tR = 5.714 min; MS m/z 459.3 [M+1]+.
N-Methyl-4-(6-(propylamino)-1-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-1H-
pyrazolo[3,4-d]pyrimidin-3-yl)benzenesulfonamide (16)—The title compound 16
(0.058 g, 63% over 2 steps) was prepared according to general procedure C from 4-(2-
bromoethyl)tetrahydro-2H-pyran (0.048 g, 0.25 mmol) as a white solid. 1 H NMR (400
MHz, CDCl3) δ 8.95 (s, 1H), 8.10–8.03 (m, 2H), 7.99–7.93 (m, 2H), 5.38 (bs, 1H), 4.47–
4.33 (m, 3H), 3.95 (dd, J = 11.5, 3.5 Hz, 2H), 3.49 (dd, J = 13.1, 6.8 Hz, 2H), 3.33 (td, J =
11.7, 1.8 Hz, 2H), 2.71 (d, J = 5.4 Hz, 3H), 1.97–1.86 (m, 2H), 1.76 (d, J = 12.7 Hz, 2H),
1.65 (dt, J = 12.7, 7.4 Hz, 2H), 1.55–1.30 (m, 5H), 0.98 (t, J = 7.3 Hz, 3H); LC-MS: 97%
purity, tR = 5.835 min; MS m/z 473.3 [M+1]+.
4-(1-Cyclohexyl-6-(propylamino)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-N-
methylbenzene sulfonamide (17)—The title compound 17 (0.035 g, 40% over 2 steps)
was prepared according to general procedure D from chlorocyclohexane (0.071 g, 0.60
mmol) as a white solid. 1H NMR (400 MHz, CDCl3) δ 8.94 (s, 1H), 8.10–8.03 (m, 2H),
7.99–7.92 (m, 2H), 5.30 (bs, 1H), 4.68–4.56 (m, 1H), 4.33 (q, J = 5.4 Hz, 1H), 3.52 (dd, J =
12.9, 7.0 Hz, 2H), 2.70 (d, J = 5.4 Hz, 3H), 2.16–1.89 (m, 6H), 1.77 (d, J = 12.7 Hz, 1H),
1.66 (dt, J = 14.8, 7.3 Hz, 2H), 1.54–1.28 (m, 5H), 0.99 (t, J = 7.3 Hz, 3H); LC-MS: >97%
purity, tR = 6.358 min; MS m/z 443.2 [M+1]+.
trans-4-(3-Bromo-6-(propylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-
yl)cyclohexanol—A solution of 4 (2.70 g, 10 mmol) and cis-4-chlorocyclohexanol (4.04
g, 30 mmol) in DMF (50 mL) was added K2CO3 (5.52 g, 40 mmol). The reaction mixture
was heated at 150 °C for overnight, quenched with water at room temperature and extracted
with EtOAc (3x). The combined organic layer was dried (Na2SO4) and concentrated. The
residue was purified by an Isco silica gel column to afford the title compound (1.83 g, 52%)
as a white solid. 1H NMR (400 MHz, CD3OD) δ 8.49 (s, 1H), 4.59–4.41 (m, 1H), 3.69–3.56
(m, 1H), 3.42 (t, J = 7.1 Hz, 2H), 2.13–2.00 (m, 4H), 1.98–1.89 (m, 2H), 1.66–1.56 (m, 2H),
1.52–1.36 (m, 4H), 0.96 (t, J = 7.4 Hz, 3H); 13C NMR (100 MHz, dmso-d6) δ 161.6, 155.0,
153.4, 119.1, 110.3, 107.7, 68.3, 55.5, 34.6, 30.9, 29.8, 20.0, 14.1; MS m/z 369.1 [M+H]+.
trans-N-(4-(6-(Butylamino)-1-(4-hydroxycyclohexyl)-1H-pyrazolo[3,4-
d]pyrimidin-3-yl)phenyl)methanesulfonamide (18)—The title compound 18 (0.008
g, 18%) was prepared according to general procedure B from (4-
(methylsulfonamido)phenyl)boronic acid (0.033 g, 0.15 mmol) as a white solid. 1H NMR
(400MHz, CDCl3) δ 8.76 (s, 1H), 7.76–7.72 (m, 2H), 7.28–7.24 (m, 2H), 4.56–4.48 (m,
1H), 3.71–3.61 (m, 1H), 3.42–3.39 (m, 1H), 3.29–3.27 (m, 2H), 2.92 (s, 3H), 2.14–2.02 (m,
4H), 1.97–1.90 (m, 2H), 1.61–1.53 (m, 2H), 1.47–1.32 (m, 6H), 0.90 (t, J = 7.36 Hz, 3H);
LC-MS: >97% purity, tR = 5.538 min; MS m/z 459.3 [M+1]+.
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d]pyrimidin-3-yl)benzenesulfonic acid (19)—(General Procedure E) A mixture of
trans-4-(3-bromo-6-(propylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)cyclohexanol (0.055
g, 0.15 mmol), K3PO4 (0.063 g, 0.30 mmol), 4-boronobenzenesulfonic acid (0.045 g, 0.225
mmol), Pd(PPh3)4 (0.017 g, 0.015 mmol), dioxane (2.0 mL) and H2O (0.5 mL) in a 10 mL
microwave tube was heated under microwave irradiation at 150 °C for 10 min. After cooling
to room temperature, the mixture was quenched with H2O and extracted with EtOAc (3x).
The combined organic layer was dried (Na2SO4) and concentrated. The residue was filtered
through a plug of Celite and then purified by prep-HPLC to afford the title compound 19
(0.027 g, 30%) as a white solid. 1H NMR (400 MHz, CD3OD) δ 9.19 (s, 1H), 8.05–7.93 (m,
4H), 4.77–4.61 (m, 1H), 3.73 (tt, J = 10.7, 4.1 Hz, 1H), 3.57 (t, J = 7.1 Hz, 2H), 2.31–2.02
(m, 6H), 1.77–1.67 (m, 2H), 1.61–1.44 (m, 4H), 1.03 (t, J = 7.4 Hz, 3H); LC-MS: >97%
purity, tR = 4.890 min; MS m/z 444.2 [M-1]−.
trans-4-(6-(Butylamino)-1-(4-hydroxycyclohexyl)-1H-pyrazolo[3,4-
d]pyrimidin-3-yl)benzenesulfonamide (20)—The title compound 20 (0.064 g, 71%)
was prepared according to general procedure E from 4-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)benzenesulfonamide (0.086 g, 0.306 mmol) as a white solid. 1H NMR
(400 MHz, CD3OD+CDCl3) δ 8.74 (s, 1H), 7.87–7.78 (m, 4H), 4.46–4.43 (m, 1H), 3.59–
3.55 (m, 1H), 3.33 – 3.28 (m, 2H), 2.03 – 1.93 (m, 4H), 1.90 – 1.85 (m, 2H), 1.50 – 1.45 (m,
2H), 1.39–1.33 (m, 2H), 1.30–1.25 (m, 2H), 1.08–1.06 (m, 3H), 0.80 (t, J = 7.4 Hz, 3H);
LC-MS: 97% purity, tR = 5.147 min; MS m/z 445.2 [M+1]+.
trans-4-(6-(Butylamino)-1-(4-hydroxycyclohexyl)-1H-pyrazolo[3,4-
d]pyrimidin-3-yl)-N-propylbenzenesulfonamide (21)—The title compound 21 (0.019
g, 13%) was prepared according to general procedure B from (4-(N-
propylsulfamoyl)phenyl)boronic acid (0.109 g, 0.45 mmol) as a white solid. 1H NMR
(400MHz, CDCl3) δ 8.83 (s, 1H), 7.98 (s, 4H), 4.68–4.62 (m, 1H), 4.42 (t,, J = 6.16 Hz 1H),
3.87–3.81 (m, 1H), 3.57–3.51 (m, 2H), 2.98 (dd, J = 6.95, 13.46 Hz, 2H), 2.25–2.16 (m,
4H), 2.10–2.07 (m, 2H), 1.71 (dt, J = 7.43, 14.83 Hz, 2H), 1.60–1.42 (m, 6H), 1.00 (t, J =
7.36 Hz, 3H), 0.89 (t, J = 7.40 Hz, 3H); LC-MS: >97% purity, tR = 6.217 min; MS m/z
487.3 [M+1]+.
trans-4-(6-(Butylamino)-1-(4-hydroxycyclohexyl)-1H-pyrazolo[3,4-
d]pyrimidin-3-yl)-N-isopropylbenzenesulfonamide (22)—The title compound 22
(0.016 g, 13%) was prepared according to general procedure B from (4-(N-
isopropylsulfamoyl)phenyl)boronic acid (0.095 g, 0.39 mmol) as a white solid. 1H NMR
(400MHz, CDCl3) δ 8.91 (s, 1H), 8.00 (dd, J = 8.62, 20.77 Hz, 4H), 4.69–4.61 (m, 1H), 4.26
(d, J = 7.61 Hz, 1H), 3.88–3.80 (m, 1H), 3.57–3.48 (m, 2H ), 2.27–2.18 (m, 4H), 2.07 (d, J =
10.85 Hz, 2H), 1.71–1.53 (m, 6H), 1.47 (dd, J = 7.36, 14.90 Hz, 2H), 1.11 (d, J = 6.52 Hz,
6H), 0.99 (t, J = 7.34 Hz, 3H); LC-MS: >97% purity, tR = 5.826 min; MS m/z 487.3 [M
+1]+.
4-(6-(Butylamino)-1-(trans-4-hydroxycyclohexyl)-1H-pyrazolo[3,4-
d]pyrimidin-3-yl)-N-cyclopropylbenzenesulfonamide (23)—The title compound 23
(0.003 g, 4%) was prepared according to general procedure E from (4-(N-
cyclopropylsulfamoyl)phenyl)boronic acid (0.090 g, 0.375 mmol) as a white solid. 1H NMR
(400 MHz, CD3OD). δ 9.11 (s, 1H), 8.17 (d, J = 8.6 Hz, 2H), 8.00 (d, J = 8.6 Hz, 2H), 4.73–
4.63 (m, 1H), 3.79–3.67 (m, 1H), 3.51 (t, J = 7.1 Hz, 2H), 2.30–2.01 (m, 7H), 1.69 (td, J =
14.7, 7.4 Hz, 2H), 1.61–1.42 (m, 4H), 1.01 (t, J = 7.4 Hz, 3H), 0.62–0.47 (m, 4H); LC-MS:
95% purity, tR = 5.957 min; MS m/z 485.0 [M+1]+.
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d]pyrimidin-3-yl)-N-cyclopentylbenzenesulfonamide (24)—The title compound 24
(0.015 g, 10%) was prepared according to general procedure B from (4-(N-
cyclopentylsulfamoyl)phenyl)boronic acid (0.121 g, 0.45 mmol) as a white solid. 1H NMR
(400MHz, CDCl3) δ 8.82 (s, 1H), 7.99 (q, J = 8.67 Hz, 4H), 4.68–4.64 (m, 1H), 4.44 (d, J =
7.34Hz, 1H), 3.86–3.82 (m, 1H), 3.67 (dd, J = 6.82, 13.53 Hz, 1H), 3.55–3.50 (m, 2H),
2.22–2.16 (m, 4H), 2.10–2.07 (m, 2H), 1.84 (dd, J = 5.70, 12.36 Hz, 2H), 1.71 (dd, J = 7.63,
14.79 Hz, 2H), 1.63–1.57 (m, 4H), 1.54–1.48 (m, 4H), 1.40–1.35 (m, 2H), 1.00 (t, J = 7.35
Hz, 3H); LC-MS: 95 % purity, tR = 6.186 min; MS m/z 513.3 [M+1]+.
trans-4-(6-(Butylamino)-1-(4-hydroxycyclohexyl)-1H-pyrazolo[3,4-
d]pyrimidin-3-yl)-N-cyclohexylbenzenesulfonamide (25)—The title compound 25
(0.015 g, 11%) was prepared according to general procedure B from (4-(N-
cyclohexylsulfamoyl)phenyl)boronic acid (0.110 g, 0.39 mmol) as a white solid. 1H NMR
(400MHz, CDCl3) δ 8.95 (s, 1H), 8.04 (d, J = 8.61 Hz, 2H), 7.97 (d, J = 8.59 Hz, 2H), 5.36
(brs, 1H), 4.67–4.64 (m, 1H), 4.34 (d, J = 7.55 Hz, 1H), 3.87–3.80 (m, 1H), 3.52 (dd, J =
7.03, 12.98 Hz, 2H), 3.24–3.15 (m, 1H), 2.28–2.18 (m, 4H), 2.09–2.06 (m, 2H), 1.82–1.79
(m, 2H), 1.67–1.56 (m, 6H), 1.52–1.46 (m, 4H), 1.27–1.14 (m, 6H), 1.00 (t, J = 7.35 Hz,
3H); LC-MS: >97% purity, tR = 6.171 min; MS m/z 527.0 [M+1]+.
trans-4-(6-(Butylamino)-1-(4-hydroxycyclohexyl)-1H-pyrazolo[3,4-
d]pyrimidin-3-yl)-N-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide (26)—The
title compound 26 (0.016 g, 10%) was prepared according to general procedure B from (4-
(N-(tetrahydro-2H-pyran-4-yl)sulfamoyl)phenyl)boronic acid (0.128 g, 0.45 mmol) as a
white solid. 1H NMR (400MHz, CDCl3) δ 9.44 (brs, 1H), 8.92 (s, 1H), 8.00 (q, J = 8.67 Hz,
4H), 4.69–4.61 (m, 2H), 3.90–3.84 (m, 4H), 3.55 (t, J = 7.04 Hz, 2H), 3.43–3.33 (m, 2H),
2.21–2.07 (m, 6H), 1.79–1.68 (m, 4H), 1.60–1.44 (m, 6H), 1.00 (t, J = 7.36 Hz, 3H); LC-
MS: 95% purity, tR = 5.747 min; MS m/z 529.3 [M+1]+.
trans-4-(6-(Butylamino)-1-(4-hydroxycyclohexyl)-1H-pyrazolo[3,4-
d]pyrimidin-3-yl)-N-(4-fluorophenyl)benzenesulfonamide (27)—The title
compound 27 (0.009 g, 6%) was prepared according to general procedure B from 4-(N-(4-
fluorophenyl)sulfamoyl)phenyl)boronic acid (0.133 g, 0.45 mmol) as a white solid. 1H
NMR (400MHz, CDCl3) δ 9.38 (s, 1H), 8.82 (s, 1H), 7.94–7.89 (m, 2H), 7.85–7.81 (m, 2H),
7.09–7.05 (m, 2H), 6.98–6.94 (m, 2H), 6.57 (s, 1H), 4.67–4.61 (m, 1H), 3.98–3.80 (m, 1H),
3.57–3.51 (m, 2H), 2.22–2.08 (m, 6H), 1.71 (dt, J = 7.29, 14.74 Hz, 2H), 1.62–1.57 (m, 2H),
1.45 (dt, J = 7.37, 14.45 Hz, 2H), 0.99 (t, J = 7.38 Hz, 3H); LC-MS: >97% purity, tR = 6.198
min; MS m/z 539.3 [M+1]+.
trans-tert-Butyl 4-((4-(6-(butylamino)-1-(4-hydroxycyclohexyl)-1H-pyrazolo[3,4-
d]pyrimidin-3-yl)phenylsulfonamido)methyl)piperidine-1-carboxylate (29)—The
title compound 29 (0.011 g, 9%) was prepared according to general procedure B from (4-(N-
((1-(tert-butoxycarbonyl)piperidin-4-yl)methyl)sulfamoyl)phenyl)boronic acid (0.119 g,
0.30 mmol, 1.5 eq) as a white solid. 1H NMR (400MHz, CDCl3+CD3OD) δ 8.78 (s, 1H),
7.90 (d, J = 8.44 Hz, 2H), 7.80 (d, J = 7.34 Hz, 2H), 4.46–4.43 (m, 1H), 3.91 (d, J = 12.95
Hz, 2H), 3.63–3.61 (m, 1H), 2.36 (t, J = 7.08 Hz, 2H), 3.22 (dt, J = 1.61, 3.24 Hz, 3H), 2.65
(d, J = 6.62 Hz, 2H), 2.54–2.51 (m, 2H), 2.08–2.00 (m, 4H), 1.93–1.90 (m, 2H), 1.58–1.46
(m, 4H), 1.31 (s, 12H), 0.97–0.91 (m, 2H), 0.89 (t, J = 7.35 Hz, 3H); LC-MS: 96% purity, tR
= 6.305 min; MS m/z 642.4 [M+1]+.
trans-4-(6-(Butylamino)-1-(4-hydroxycyclohexyl)-1H-pyrazolo[3,4-
d]pyrimidin-3-yl)-N-(piperidin-4-ylmethyl)benzenesulfonamide (28)—A mixture
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29 (20 mg, 0.03 mmol) and TFA (2.3 mL) in dichloromethane (4.7 mL) were stirred at room
temperature for 2.0 h, then diluted with dichloromethane (20 mL) and washed with a
saturated aqueous NaHCO3 solution, water and brine. The organic layer was dried (Na2SO4)
and concentrated to afford the title compound 28 (12.7 mg, 75%) as a white solid. 1H NMR
(400MHz, CDCl3+CD3OD) δ 8.25 (s, 1H), 7.23 (d, J = 8.45 Hz, 2H), 7.14 (d, J = 8.20 Hz,
2H), 3.85–3.80 (m, 1H), 2.96–2.91 (m, 1H), 2.72 (t, J = 7.15 Hz, 2H), 2.54–2.52 (m, 3H),
2.07–1.99 (m, 4H), 1.41–1.32 (m, 4H), 1.26–1.23 (m, 2H), 1.12 (d, J = 13.63 Hz, 2H), 0.98–
0.94 (m, 1H), 0.91–0.84 (m, 2H), 0.79–0.75 (m, 2H), 0.67–0.56 (m, 4H), 0.17 (t, J = 7.35
Hz, 3H); LC-MS: >97% purity, tR = 4.975 min; MS m/z 542.3 [M+1]+.
trans-1-(4-(6-(Butylamino)-1-(4-hydroxycyclohexyl)-1H-pyrazolo[3,4-
d]pyrimidin-3-yl)phenylsulfonamido)-N-(4-
fluorophenyl)cyclopropanecarboxamide (30)—The title compound 30 (0.009 g, 7%)
was prepared according to general procedure B from (4-(N-(1-((4-
fluorophenyl)carbamoyl)cyclopropyl)sulfamoyl)phenyl)boronic acid (0.160 g, 0.42 mmol,
2.0 eq) as a white solid. 1H NMR (400MHz, CD3OD) δ 9.17 (s, 1H), 8.95 (s, 1H), 8.06 (d, J
= 8.54 Hz, 2H), 7.96 (d, J = 8.33 Hz, 2H), 7.34–7.31 (m, 2H), 6.90–6.86 (m, 2H), 4.68–4.62
(m, 1H), 3.75–3.70 (m, 1H), 3.50 (t, J = 7.90 Hz, 2H), 2.24–2.13 (m, 4H), 2.06–2.03 (m,
2H), 1.71–1.64 (m, 2H), 1.58–1.38 (m, 6H), 1.10 (dd, J = 4.67, 7.89 Hz, 2H), 1.00 (t, J =
7.36 Hz, 3H); LC-MS: 96% purity, tR = 6.051 min; MS m/z 622.3 [M+1]+.
4-(6-(Butylamino)-1-(trans-4-hydroxycyclohexyl)-1H-pyrazolo[3,4-
d]pyrimidin-3-yl)-N,N-dimethylbenzenesulfonamide (31)—The title compound 31
(0.052 g, 74%) was prepared according to general procedure E from (4-(N,N-
dimethylsulfamoyl)phenyl)boronic acid (0.052 g, 0.225 mmol) as a white solid. 1H NMR
(400 MHz, CDCl3) δ 8.94 (s, 1H), 8.07 (d, J = 8.4 Hz, 2H), 7.88 (d, J = 8.3 Hz, 2H), 5.34
(bs, 1H), 4.73–4.59 (m, 1H), 3.90–3.76 (m, 1H), 3.52 (dd, J = 13.0, 6.8 Hz, 2H), 2.75 (s,
6H), 2.29–2.15 (m, 4H), 2.13–2.02 (m, 2H), 1.66 (dt, J = 14.9, 7.3 Hz, 2H), 1.59–1.52 (t, J =
10.2 Hz, 3H), 1.47 (dd, J = 15.0, 7.4 Hz, 2H), 1.00 (t, J = 7.3 Hz, 3H); LC-MS: 97% purity,
tR = 6.011 min; MS m/z 473.3 [M+1]+.
N-(tert-Butyl)-4-(6-(butylamino)-1-(trans-4-hydroxycyclohexyl)-1H-
pyrazolo[3,4-d]pyrimidin-3-yl)-N-methylbenzenesulfonamide (32)—The title
compound 32 (0.058 g, 76%) was prepared according to general procedure E from ((4-(N-
(tert-butyl)-N-methylsulfamoyl)phenyl)boronic acid (0.061 g, 0.225 mmol) as a white
solid. 1H NMR (400 MHz, CDCl3) δ 8.93 (s, 1H), 8.07–7.97 (m, 2H), 7.96–7.89 (m, 2H),
5.40 (bs, 1H), 4.73–4.58 (m, 1H), 3.91–3.76 (m, 1H), 3.52 (dd, J = 12.9, 6.9 Hz, 2H), 3.01
(s, 3H), 2.30–2.14 (m, 4H), 2.07 (d, J = 10.8 Hz, 2H), 1.68–1.44 (m, 7H), 1.38 (d, J = 4.8
Hz, 9H), 0.99 (t, J = 7.3 Hz, 3H); LC-MS: 96% purity, tR = 6.328 min; MS m/z 515.3 [M
+1]+.
trans-4-(3-(4-(Azetidin-1-ylsulfonyl)phenyl)-6-(butylamino)-1H-pyrazolo[3,4-
d]pyrimidin-1-yl)cyclohexanol (33)—The title compound 33 (0.054 g, 74%) was
prepared according to general procedure E from (4-(azetidin-1-ylsulfonyl)phenyl)boronic
acid (0.054 g, 0.225 mmol) as a white solid. 1H NMR (400 MHz, CDCl3) δ 8.96 (s, 1H),
8.11 (d, J = 8.3 Hz, 2H), 7.95 (d, J = 8.2 Hz, 2H), 5.33 (s, 1H), 4.75–4.57 (m, 1H), 3.92–
3.74 (m, 5H), 3.53 (dd, J = 13.1, 6.7 Hz, 2H), 2.32–2.16 (m, 4H), 2.15–2.03 (m, 4H), 1.66
(dt, J = 14.8, 7.2 Hz, 2H), 1.55–1.50 (m, 3H), 1.45 (dd, J = 14.6, 7.3 Hz, 2H), 1.00 (t, J = 7.3
Hz, 3H); LC-MS: >97% purity, tR = 5.992 min; MS m/z 485.3 [M+1]+.
trans-4-(6-(Butylamino)-3-(4-(pyrrolidin-1-ylsulfonyl)phenyl)-1H-pyrazolo[3,4-
d]pyrimidin-1-yl)cyclohexanol (34)—The title compound 34 (0.020 g, 27%) was
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prepared according to general procedure E from (4-(pyrrolidin-1-ylsulfonyl)phenyl)boronic
acid (0.096 g, 0.375 mmol) as a white solid. 1H NMR (400 MHz, CD3OD). δ 9.20 (s, 1H),
8.20 (d, J = 8.5 Hz, 2H), 7.98 (d, J = 8.5 Hz, 2H), 4.75–4.64 (m, 1H), 3.78–3.67 (m, 1H),
3.55 (t, J = 7.1 Hz, 2H), 3.32–3.23 (m, 4H), 2.30–2.02 (m, 6H), 1.85–1.64 (m, 6H), 1.62–
1.42 (m, 4H), 1.02 (t, J = 7.4 Hz, 3H); LC-MS: >97% purity, tR = 6.100 min; MS m/z 499.0
[M+1]+.
trans-4-(6-(Butylamino)-3-(4-(morpholinosulfonyl)phenyl)-1H-pyrazolo[3,4-
d]pyrimidin-1-yl)cyclohexanol (35, UNC1062)—The title compound 35 (0.063 g,
82%) was prepared according to general procedure E from 4-((4-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)phenyl)sulfonyl)morpholine (0.079 g, 0.225 mmol) as a white solid. 1H
NMR (400 MHz, CD3OD). δ 9.20 (s, 1H), 8.26–8.20 (m, 2H), 7.95–7.89 (m, 2H), 4.75–4.64
(m, 1H), 3.79–3.68 (m, 1H), 3.73 (dd, J = 10.2, 5.7 Hz, 4H), 3.55 (t, J = 7.1 Hz, 2H), 3.08–
2.97 (m, 4H), 2.36–2.01 (m, 6H), 1.76–1.65 (m, 2H), 1.62–1.42 (m, 4H), 1.02 (t, J = 7.4 Hz,
3H); 13C NMR (100 MHz, DMSO-d6) δ 160.6, 155.2, 154.0, 140.6, 136.9, 133.7, 128.3,
127.0, 105.1, 68.0, 65.3, 55.0, 45.9, 40.3, 34.2, 30.6, 29.4, 19.6, 13.7; LC-MS: >97% purity,




The title compound 36 (0.065 g, 66%) was prepared according to general procedure E from
(4-((4-(morpholine-4-carbonyl)piperidin-1-yl)sulfonyl)phenyl)boronic acid (0.091 g, 0.24
mmol) as a white solid. 1H NMR (400 MHz, CD3OD+CDCl3) δ 9.21 (s, 1H), 8.37–8.28 (m,
2H), 8.24–8.16 (m, 2H), 5.04–4.94 (m, 1H), 4.60–4.38 (m, 2H), 4.23–4.07 (m, 3H), 3.99–
3.94 (m, 3H), 3.93–3.82 (m, 4H), 3.78–3.68 (m, 2H), 2.91–2.82 (m, 2H), 2.76 (ddd, J = 10.4,
7.2, 3.9 Hz, 1H), 2.61–2.46 (m, 4H), 2.46–2.36 (m, 2H), 2.30–2.17 (m, 2H), 2.15–2.06 (m,
2H), 2.06–1.98 (m, 2H), 1.98–1.86 (m, 2H), 1.85–1.74 (m, 2H), 1.33 (t, J = 7.4 Hz, 3H);
LC-MS: 96% purity, tR = 5.468 min; MS m/z 626.3 [M+1]+.
Microfluidic Capillary Electrophoresis (MCE) Assay
Activity assays were performed in a 384 well, polypropylene microplate with a final volume
of 50 μL in 50 mM Hepes, Ph 7.4 containing 10 mM MgCl2, 1.0 mM DTT, 0.01% Triton
X-100, 0.1% Bovine Serum Albumin (BSA), using 1.0 μM fluorescent substrate (table 3)
and ATP at Km for each enzyme (Table 3). All reactions were terminated by addition of 20
μL of 70 mM EDTA. Phosphorylated and unphosphorylated substrate peptides (Table 3)
were separated following a 180 min incubation on a LabChip EZ Reader equipped with a
12-sipper chip in separation buffer supplemented with 1 x CR-8 and analyzed using EZ
Reader software.
Morrison Ki Measurement
Inhibition of Mer kinase by UNC1062 was measured in the MCE assay using the Morrison
Tight-Binding Method17b. Reactions were performed in a 384 well, polypropylene
microplate in a final volume of 80 μL in 50 mM Hepes, Ph 7.4 containing 10 mM MgCl2,
1.0 mM DTT, 0.01% Triton X-100, 0.1% Bovine Serum Albumin (BSA), and 5.0 μM ATP.
Compounds were tested in 20 dilution (1.5 fold) dose curves spanning a concentration range
of 60 nM to 0.027 nM, 2.0 nM Mer, 1.0 μM Peptide substrate, and 5.0 μM ATP, final. To
40 μL of enzyme (4 nM Mer), 8.0 μL of compound in 10% DMSO was added and allowed
to incubate for 10 min followed by addition of 32 μL of substrate mix (containing 2.5 μM
peptide substrate and 12.5 μM ATP).
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Kinetic reads were taken from 7.0 to 209 min, 12 reads total, on an EZReader, using
upstream voltage = −2250 V, downstream voltage = −500 V and pressure = −1.0 psi (sip
time 0.2 sec, buffer 30 sec). The steady-state velocity was analyzed by linear regression of
the Peptide as percent-conversion/min, and a plot of nM compound (UNC1062) vs. velocity
was fit to the Morison equation using GraphPad Prism 5.0., Y=Vo*(1-((((Et+X+(Ki*(1+(S/
Km))))-(((Et+X+(Ki*(1+(S/Km))))^2)-4*Et*X)^0.5))/(2*Et))) (Figure 5). The total enzyme
concentration (Et) was fixed to 0.855 nM as determined from previous titration studies (data
not shown).17b (Y = velocity, X = inhibitor concentration).
For UNC1062, the Morrison Ki was 0.33 ± 0.083 nM (n=3, error reported as S.D.).
hERG Binding Assay
Assay Buffer: Hank’s Balanced Salt Solution, 20 mM HEPES, 2.5 mM probenecid, pH 7.4,
membrane potential sensitive dye (Molecular Devices).
To screen for drugs that block or open HERG K+ channels, we employ a fluorescence-based
membrane potential assay (Molecular Devices). HEK293 cells stably expressing
recombinant human HERG (provided by Dr. J. Overholt, Case Western Reserve Univeristy,
Cleveland, OH; cells originally from Drs. A. Brown and E. Ficker, MetroHealth Medical
Center, Cleveland, OH) are seeded in poly-L-lysine-coated 96-well plates (45,000 cells/100
μL DMEM supplemented with 10% fetal bovine serum/well) one day prior to assay. The
next day, the medium is removed and replaced with 30 μL/well of assay buffer containing
membrane potential dye (Molecular Devices) (the lyophilized dye is reconstituted with 15
mL of assay buffer). After a 15 min incubation at 37 degrees centigrade, 30 μL/well of 2X
dilutions of terfenadine (a known HERG blocker used as a reference compound) or test
compound (final assay concentration ranging from 0.1 nM to 10 μM) are added to the cells
(each concentration assayed in triplicate). Baseline fluorescence (excitation 530 nM,
emission 565 nM) is measured over 15 min, then 140 μL of depolarization solution (143
mM KCl in distilled water) containing test or reference compound (1x) are added to the cells
and fluorescence is recorded for 3 min. Raw fluorescence data are analyzed by GraphPad
Prism 4.0.
Cell Based Assays for Mer Kinase Inhibition
697, BT-12, A549, or Colo699 cells were cultured in the presence of UNC1062 or vehicle
only for 1.0 h (697, BT-12) or 72 h (A549, Colo699). Pervanadate solution was prepared
fresh by combining 20 mM sodium orthovanadate in 0.9x PBS in a 1:1 ratio with 0.3% (w/
w) hydrogen peroxide in PBS for 15–20 min at room temperature. Cultures were treated
with 120 μM pervanadate prior to collection for preparation of whole cell lysates,
immunoprecipitation of Mer, and analysis by western blot.
697, A549, and Colo699 cells were treated with pervanadate for 3.0, 5.0, and 1.0 min
respectively. Cell lysates were prepared in 50 mM HEPES pH 7.5, 150 mM NaCl, 10 mM
EDTA, 10% glycerol, and 1% Triton X-100, supplemented with protease inhibitors (Roche
Molecular Biochemicals, #11836153001). Mer protein was immunoprecipitated with a
monoclonal anti-Mer antibody (R&D Systems, #MAB8912) and Protein G agarose beads
(InVitrogen). Phospho-Mer was detected by western blot using a polyclonal anti-phospho-
Mer antibody raised against a peptide derived from the tri-phosphorylated activation loop of
Mer. Nitrocellulose membranes were stripped and total Mer protein was detected using a
second anti-Mer antibody (Epitomics Inc., #1633-1). For 697 cells, relative phosphorylated
and total Mer protein levels were determined by densitometry and IC50 values were
determined by non-linear regression.
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Confluent BT-12 cultures were treated with pervanadate for 15 min. Cell lysates were
prepared in 20 mM HEPES pH 7.5, 500 mM NaCl, 5.0 mM EDTA, 10% glycerol, and 1%
Triton X-100, supplemented with protease inhibitors (10 μg/mL leupeptin, 10 μg/mL
phenylmethylsulfonyl fluoride, and 20 μg/ml aprotinin) and phosphatase inhibitors (50 mM
sodium fluoride and 1.0 mM sodium orthovanadate) and Mer protein was
immunoprecipitated using a custom polyclonal rabbit anti-Mer antisera raised against a
peptide derived from the N-terminus of Mer and Protein A agarose beads (Santa Cruz
Biotechnology). Phosphotyrosine-containing proteins were detected by western blot with a
monoclonal HRP-conjugated anti-phosphotyrosine antibody (Santa Cruz Biotechnology,
#sc-508). Antibodies were stripped from membranes and total Mer levels were determined
using a custom polyclonal rabbit anti-Mer raised against a peptide derived from the catalytic
domain of Mer.
Soft Agar Colony Formation Assays
BT-12 cells (10,000 cells) were cultured in 2.0 mL of 0.35% soft agar containing 0.5x RPMI
medium, 7.5% FBS, and the indicated concentrations of UNC1062 or DMSO vehicle only
and overlaid with 0.5 mL of 1x RPMI medium containing 15% FBS and UNC1062 or
DMSO vehicle only. Medium and UNC1062 or vehicle were refreshed 2 times per week.
Colonies were stained with thiazolyl blue tetrazolium bromide (Sigma Aldrich, #M5655)
and counted after 3 weeks.
A549 or Colo699 cells (15,000 cells) were cultured in 1.5 mL of 0.35% soft agar containing
1x RPMI medium and 10% FBS and overlaid with 2.0 mL of 1x RPMI medium containing
10% FBS and the indicated concentrations of UNC1062 or DMSO vehicle only. Medium
and UNC1062 or vehicle were refreshed 3 times per week. Colonies were stained with
nitrotetrazolium blue chloride (Sigma Aldrich, #N6876) and counted after 2 weeks.
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1. Discovery of pyazolopyrimidine sulfonamides as potent and selective Mer
inhibitors.
2. UNC1062 selectively inhibits Mer both in purified enzymes and intact cell
systems.
3. UNC1062 inhibits the colony formation of multiple tumor cell lines in soft agar.
4. The anti-tumor activity of UNC1062 further validates Mer as a therapeutic
target.
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The structures and enzymatic activities of 1 and 2.
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Figure 2. UNC1062 inhibits accumulation of activated Mer protein in acute leukemia cells
697 cell cultures were treated with the indicated concentrations of UNC1062 for 1 h.
Pervanadate was added to cultures for 3 min to stabilize the phosphorylated form of Mer.
Mer was immunoprecipitated from cell lysates and total Mer protein and Mer
phosphoprotein were detected by immunoblot. A) Representative western blots. B) Relative
levels of phospho-Mer and Mer proteins were determined. Mean values +/− standard error
derived from 4 independent experiments are shown. IC50 = 6.4 nM with a 95% confidence
interval of 3.8 nM to 10.7 nM.
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Figure 3. UNC1062 inhibits Mer activation in adherent tumor cell lines
A) BT-12 pediatric rhabdoid tumor cells were treated with UNC1062 or vehicle only for 1 h
prior to the addition of pervanadate for 15 min. Cell lysates were prepared, Mer protein was
immunoprecipitated, and phospho-tyrosine and Mer protein were detected by western blot.
B) The indicated NSCLC cell lines were treated with UNC1062 or an equivalent volume of
vehicle only for 72 h prior to treatment with pervanadate for 1.0 (Colo699) or 5.0 (A549)
min. Whole cell lysates were prepared, Mer protein was immunoprecipitated, and
phosphorylated and total Mer proteins were detected by western blot. The results shown are
representative of 3 independent experiments.
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Figure 4. UNC1062 inhibits colony formation in solid tumor cell lines
A) BT-12 rhabdoid tumor cells were cultured in soft agar containing 1.0 μM UNC1062 or
vehicle only and overlaid with medium containing UNC1062 or vehicle only. Medium and
UNC1062 were refreshed twice weekly. Colonies were stained and counted. Representative
plates are shown. B) A549 and Colo699 NSCLC cells were cultured in 0.35% soft agar
overlaid with medium containing UNC1062 or vehicle only. Medium and UNC1062 were
refreshed 3 times per week. Colonies were stained and counted. Mean values ± SEM derived
from 3 independent experiments are shown. *Statistically significant results were
determined using the student’s paired t test (* p < 0.02, ** p < 0.001 relative to vehicle
only).
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The synthetic routes for sulfonamide analogues
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Table 1
Preliminary SAR at the R2 position
Compound R2 IC50 (nM)a
Mer Axl Tyro3
2 3.5 59 27
7 18 140 130
8 35 120 200
9 50 190 82
10 2.4 74 47
11 4.4 70 44
12 250 2400 860
13 130 5000 730
14 23 450 280
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Compound R2 IC50 (nM)a
Mer Axl Tyro3
15 47 620 810
16 54 360 430
17 100 26000 720
a
Values are the mean of two or more independent assays performed at the ATP Km.
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Table 2
SAR Study of R1
Compound R1 IC50 (nM)a
Mer Axl Tyro3
18 4.0 110 35
19 1.8 130 55
20 1.4 29 54
21 1.8 62 35
22 3.2 120 68
23 1.1 75 38
24 0.80 67 31
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Compound R1 IC50 (nM)a
Mer Axl Tyro3
25 1.1 350 45
26 1.2 69 28
27 9.7 6500 290
28 1.1 55 47
29 1.4 73 150
30 18 780 320
31 1.8 71 47
32 1.2 110 160
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Compound R1 IC50 (nM)a
Mer Axl Tyro3
33 1.0 42 27
34 0.65 46 22
35 1.1 85 60
36 1.4 23 76
a
Values are the mean of two or more independent assays performed at the ATP Km.
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Table 3
Assay conditions for MCE assays currently used
Kinase Peptide Substrate Kinase (nM) ATP (uM)
Mer 5-FAM-EFPIYDFLPAKKK-CONH2 2.0 5.0
Axl 5-FAM-KKKKEEIYFFF-CONH2 120 65
Tyro 5-FAM-EFPIYDFLPAKKK-CONH2 10 21
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